Table 3.
Primary indication for testing for human anti-chimeric antibodies and infliximab concentrations
| Indication, n (%) | N =155 |
|---|---|
| Loss of response | 76 (49) |
| Partial response on initiation | 34 (22) |
| Autoimmune/delayed hypersensitivity reaction | 16 (10) |
| Primary non-response | 8 (5) |
| Reintroduction after drug holiday | 7 (5) |
| Endoscopic/CTE recurrence | 6 (4) |
| Acute infusion reaction | 5 (3) |
| Unclear reason | 3 (2) |
CTE, computed tomography enterography.